Clinical Trial Update: Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating anlotinib combined with penpulimab and SBRT in metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Penpulimab
• SBRT (stereotactic body radiotherapy)

Snippet

Sponsor: Peking University Third Hospital | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN